Literature DB >> 24414863

Resveratrol improves motoneuron function and extends survival in SOD1(G93A) ALS mice.

Renzo Mancuso1, Jaume del Valle, Laura Modol, Anna Martinez, Ana B Granado-Serrano, Omar Ramirez-Núñez, Mercé Pallás, Manel Portero-Otin, Rosario Osta, Xavier Navarro.   

Abstract

Amyotrophic lateral sclerosis (ALS) is an adult onset neurodegenerative disease that causes progressive paralysis and death due to degeneration of motoneurons in spinal cord, brainstem and motor cortex. Nowadays, there is no effective therapy and patients die 2-5 years after diagnosis. Resveratrol (trans-3,4',5-trihydroxystilbene) is a natural polyphenol found in grapes, with promising neuroprotective effects since it induces expression and activation of several neuroprotective pathways involving Sirtuin1 and AMPK. The objective of this work was to assess the effect of resveratrol administration on SOD1(G93A) ALS mice. We determined the onset of symptoms by rotarod test and evaluated upper and lower motoneuron function using electrophysiological tests. We assessed the survival of the animals and determined the number of spinal motoneurons. Finally, we further investigated resveratrol mechanism of action by means of western blot and immunohistochemical analysis. Resveratrol treatment from 8 weeks of age significantly delayed disease onset and preserved lower and upper motoneuron function in female and male animals. Moreover, resveratrol significantly extended SOD1(G93A) mice lifespan and promoted survival of spinal motoneurons. Delayed resveratrol administration from 12 weeks of age also improved spinal motoneuron function preservation and survival. Further experiments revealed that resveratrol protective effects were associated with increased expression and activation of Sirtuin 1 and AMPK in the ventral spinal cord. Both mediators promoted normalization of the autophagic flux and, more importantly, increased mitochondrial biogenesis in the SOD1(G93A) spinal cord. Taken together, our findings suggest that resveratrol may represent a promising therapy for ALS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24414863      PMCID: PMC3996124          DOI: 10.1007/s13311-013-0253-y

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  75 in total

1.  Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.

Authors:  Sung-Jun Park; Faiyaz Ahmad; Andrew Philp; Keith Baar; Tishan Williams; Haibin Luo; Hengming Ke; Holger Rehmann; Ronald Taussig; Alexandra L Brown; Myung K Kim; Michael A Beaven; Alex B Burgin; Vincent Manganiello; Jay H Chung
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

2.  Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis.

Authors:  F R Wiedemann; K Winkler; A V Kuznetsov; C Bartels; S Vielhaber; H Feistner; W S Kunz
Journal:  J Neurol Sci       Date:  1998       Impact factor: 3.181

Review 3.  Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation.

Authors:  Feng Zhang; Jie Liu; Jing-Shan Shi
Journal:  Eur J Pharmacol       Date:  2010-03-31       Impact factor: 4.432

4.  Autophagy induced by resveratrol prevents human prion protein-mediated neurotoxicity.

Authors:  Jae-Kyo Jeong; Myung-Hee Moon; Bum-Chul Bae; You-Jin Lee; Jae-Won Seol; Hyung-Sub Kang; Jin-Shang Kim; Seog-Jin Kang; Sang-Youel Park
Journal:  Neurosci Res       Date:  2012-03-23       Impact factor: 3.304

5.  Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis.

Authors:  Jing Wang; Yun Zhang; Lu Tang; Nan Zhang; Dongsheng Fan
Journal:  Neurosci Lett       Date:  2011-08-27       Impact factor: 3.046

6.  SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase.

Authors:  Xiuyun Hou; Shanqin Xu; Karlene A Maitland-Toolan; Kaori Sato; Bingbing Jiang; Yasuo Ido; Fan Lan; Kenneth Walsh; Michel Wierzbicki; Tony J Verbeuren; Richard A Cohen; Mengwei Zang
Journal:  J Biol Chem       Date:  2008-05-14       Impact factor: 5.157

7.  Selective mitochondrial Ca2+ uptake deficit in disease endstage vulnerable motoneurons of the SOD1G93A mouse model of amyotrophic lateral sclerosis.

Authors:  Andrea Fuchs; Sylvie Kutterer; Tobias Mühling; Johanna Duda; Burkhard Schütz; Birgit Liss; Bernhard U Keller; Jochen Roeper
Journal:  J Physiol       Date:  2013-02-11       Impact factor: 5.182

8.  Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis.

Authors:  M E Ripps; G W Huntley; P R Hof; J H Morrison; J W Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

9.  Mitochondrial electron transport chain complex dysfunction in a transgenic mouse model for amyotrophic lateral sclerosis.

Authors:  Cheolwha Jung; Cynthia M J Higgins; Zuoshang Xu
Journal:  J Neurochem       Date:  2002-11       Impact factor: 5.372

10.  Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis.

Authors:  Zoe Fonseca-Kelly; Mayssa Nassrallah; Jorge Uribe; Reas S Khan; Kimberly Dine; Mahasweta Dutt; Kenneth S Shindler
Journal:  Front Neurol       Date:  2012-05-24       Impact factor: 4.003

View more
  69 in total

Review 1.  Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Richard S Bedlack; Nanette Joyce; Gregory T Carter; Sabrina Paganoni; Chafic Karam
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

Review 2.  Autophagy as a common pathway in amyotrophic lateral sclerosis.

Authors:  Dao K H Nguyen; Ravi Thombre; Jiou Wang
Journal:  Neurosci Lett       Date:  2018-04-04       Impact factor: 3.046

3.  Early ALS-type gait abnormalities in AMP-dependent protein kinase-deficient mice suggest a role for this metabolic sensor in early stages of the disease.

Authors:  Maxime Vergouts; Claudia Marinangeli; Caroline Ingelbrecht; Geraldine Genard; Olivier Schakman; Anthony Sternotte; André-Guilhem Calas; Emmanuel Hermans
Journal:  Metab Brain Dis       Date:  2015-07-09       Impact factor: 3.584

4.  Repurposing carbamazepine for the treatment of amyotrophic lateral sclerosis in SOD1-G93A mouse model.

Authors:  Jing-Jing Zhang; Qin-Ming Zhou; Sheng Chen; Wei-Dong Le
Journal:  CNS Neurosci Ther       Date:  2018-04-14       Impact factor: 5.243

5.  Quantum chemical and molecular mechanics studies on the assessment of interactions between resveratrol and mutant SOD1 (G93A) protein.

Authors:  E Srinivasan; R Rajasekaran
Journal:  J Comput Aided Mol Des       Date:  2018-10-28       Impact factor: 3.686

6.  Diffusion Efficiency and Bioavailability of Resveratrol Administered to Rat Brain by Different Routes: Therapeutic Implications.

Authors:  Xiao-Hong Shu; Li-Li Wang; Hong Li; Xue Song; Shun Shi; Jia-Yao Gu; Mo-Li Wu; Xiao-Yan Chen; Qing-You Kong; Jia Liu
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 7.  Research Progress on Alzheimer's Disease and Resveratrol.

Authors:  Yan Yan; Huihuang Yang; Yuxun Xie; Yuanlin Ding; Danli Kong; Haibing Yu
Journal:  Neurochem Res       Date:  2020-03-11       Impact factor: 3.996

Review 8.  Preserving Lysosomal Function in the Aging Brain: Insights from Neurodegeneration.

Authors:  Wesley Peng; Georgia Minakaki; Maria Nguyen; Dimitri Krainc
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 9.  Could Sirtuin Activities Modify ALS Onset and Progression?

Authors:  Bor Luen Tang
Journal:  Cell Mol Neurobiol       Date:  2016-12-10       Impact factor: 5.046

Review 10.  Epigenetic regulation of astrocyte function in neuroinflammation and neurodegeneration.

Authors:  Matthew Neal; Jason R Richardson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-11-04       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.